[go: up one dir, main page]

ES2177581T3 - Uso de compuestos de piperidina en el tratamiento de esquizofrenia. - Google Patents

Uso de compuestos de piperidina en el tratamiento de esquizofrenia.

Info

Publication number
ES2177581T3
ES2177581T3 ES94924708T ES94924708T ES2177581T3 ES 2177581 T3 ES2177581 T3 ES 2177581T3 ES 94924708 T ES94924708 T ES 94924708T ES 94924708 T ES94924708 T ES 94924708T ES 2177581 T3 ES2177581 T3 ES 2177581T3
Authority
ES
Spain
Prior art keywords
schizophrenia
treatment
piperidine compounds
mamphere
mammer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94924708T
Other languages
English (en)
Inventor
Franklin Porter Bymaster
Harlan E Shannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2177581T3 publication Critical patent/ES2177581T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN NUEVO METODO PARA TRATAR A UN MAMIFERO QUE SUFRA O SEA SUSCEPTIBLE A LA ESQUIZOFRENIA Y A ENFERMEDADES DE FORMA ESQUIZOFRENICA QUE COMPRENDE LA ADMINISTRACION A DICHO MAMIFERO DE UNA CANTIDAD EFECTIVA DE UN COMPUESTO DE LA FORMULA (I), EN LA QUE Z1 ES OXIGENO O AZUFRE.
ES94924708T 1993-08-19 1994-08-15 Uso de compuestos de piperidina en el tratamiento de esquizofrenia. Expired - Lifetime ES2177581T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10930093A 1993-08-19 1993-08-19

Publications (1)

Publication Number Publication Date
ES2177581T3 true ES2177581T3 (es) 2002-12-16

Family

ID=22326932

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94924708T Expired - Lifetime ES2177581T3 (es) 1993-08-19 1994-08-15 Uso de compuestos de piperidina en el tratamiento de esquizofrenia.

Country Status (23)

Country Link
EP (1) EP0734259B1 (es)
JP (1) JP3126736B2 (es)
KR (1) KR100360575B1 (es)
CN (1) CN1087936C (es)
AT (1) ATE218864T1 (es)
AU (1) AU701292B2 (es)
CA (1) CA2169839C (es)
CZ (1) CZ285030B6 (es)
DE (1) DE69430816T2 (es)
DK (1) DK0734259T3 (es)
ES (1) ES2177581T3 (es)
FI (2) FI960747L (es)
HU (1) HU221729B1 (es)
IL (1) IL110708A (es)
NO (1) NO312706B1 (es)
NZ (2) NZ336597A (es)
PT (1) PT734259E (es)
RU (1) RU2191580C2 (es)
SG (1) SG55071A1 (es)
TW (1) TW442284B (es)
UA (1) UA63876C2 (es)
WO (1) WO1995005174A1 (es)
ZA (1) ZA946324B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998404A (en) * 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5821371A (en) * 1994-10-24 1998-10-13 Eli Lilly And Comany Heterocyclic compounds and their preparation and use
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
CA2202776A1 (en) * 1994-10-31 1996-05-09 Franklin Porter Bymaster Method for treating anxiety
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US5726193A (en) * 1994-10-31 1998-03-10 Eli Lilly And Company Method for treating anxiety
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5852037A (en) * 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
EP0821956A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating disruptive behavior disorders
EP0821958A3 (en) * 1996-08-01 1998-07-08 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
PT821955E (pt) * 1996-08-01 2002-07-31 Lilly Co Eli Uso de 3-(4-hexiloxi-1,2,5-tiadiazol-3-il)-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) para o tratamento da doenca bipolar
EP0821957A3 (en) * 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
EP0821954A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating mental retardation
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
EP0821959A3 (en) * 1996-08-01 1998-09-16 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal
WO1998053820A1 (en) * 1997-05-29 1998-12-03 H. Lundbeck A/S Treatment of schizophrenia and psychosis
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
HUE044653T2 (hu) 2009-07-22 2019-11-28 PureTech Health LLC Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk
CR20210212A (es) 2018-09-28 2021-09-24 Karuna Therapeutics Inc Composiciones y métodos para tratar trastornos mejorados por medio de activación de receptor muscarínico
US11534434B2 (en) 2019-11-15 2022-12-27 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
CN115974863B (zh) * 2021-10-14 2024-12-31 南京迈诺威医药科技有限公司 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途
CN119161338A (zh) * 2024-11-25 2024-12-20 嘉兴安帝康生物科技有限公司 用作毒蕈碱受体激动剂的四氢吡啶衍生物及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse

Also Published As

Publication number Publication date
EP0734259B1 (en) 2002-06-12
DK0734259T3 (da) 2002-09-30
UA63876C2 (en) 2004-02-16
DE69430816D1 (de) 2002-07-18
FI960747L (fi) 1996-04-17
NO960619L (no) 1996-04-18
HUT75111A (en) 1997-04-28
HU221729B1 (hu) 2002-12-28
JPH09501658A (ja) 1997-02-18
ZA946324B (en) 1996-02-19
HU9600364D0 (en) 1996-04-29
RU2191580C2 (ru) 2002-10-27
IL110708A (en) 1998-12-06
CN1087936C (zh) 2002-07-24
NO312706B1 (no) 2002-06-24
CA2169839C (en) 2002-06-11
ATE218864T1 (de) 2002-06-15
CN1133008A (zh) 1996-10-09
NO960619D0 (no) 1996-02-16
PT734259E (pt) 2002-11-29
FI960747A0 (fi) 1996-02-19
DE69430816T2 (de) 2002-12-19
CZ42696A3 (en) 1996-11-13
NZ336597A (en) 2001-02-23
CA2169839A1 (en) 1995-02-23
IL110708A0 (en) 1994-11-11
SG55071A1 (en) 1998-12-21
AU701292B2 (en) 1999-01-21
TW442284B (en) 2001-06-23
NZ271311A (en) 1999-09-29
JP3126736B2 (ja) 2001-01-22
KR100360575B1 (ko) 2003-03-10
AU7490294A (en) 1995-03-14
CZ285030B6 (cs) 1999-05-12
EP0734259A1 (en) 1996-10-02
FI20050461L (fi) 2005-04-29
WO1995005174A1 (en) 1995-02-23
KR960703592A (ko) 1996-08-31

Similar Documents

Publication Publication Date Title
ES2177581T3 (es) Uso de compuestos de piperidina en el tratamiento de esquizofrenia.
CR11037A (es) Derivados de 4-tetrazolil -4fenilpiperidina para tratar el dolor (divisional)
FI972580A0 (fi) Valmisteita ja menetelmiä ihoärsytyksen vähentämiseksi
ECSP941135A (es) Antagonistas triciclicos de vasopresina de benzacepina
CO5011115A1 (es) Compuestos y metodos quimioquina
CR10167A (es) "uso de derivados de sulfamida heterociclica benzo-fusionada para el tratamiento de dolor"
BR0005276A (pt) Compostos para o tratamento de disfução sexual feminina
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
FI942052A0 (fi) Heteroaryylipiperidiinejä, -pyrrolidiinejä ja -piperatsiineja ja niiden käyttö antipsykoottisina ja anlgeettisina aineina
BR0310092A (pt) Combinação de compostos orgânicos
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
NO307687B1 (no) Anvendelse av riluzol ved fremstilling av medikamenter for behandling av neuro-AIDS
SE0301882D0 (sv) New use I
BR9913833A (pt) Método para tratar diabetes, empregando em inibidor de ap2 e combinação
MX9304435A (es) Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii.
BR9809115A (pt) Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt
MX9300603A (es) Derivados tiaciclicos de piperidinilo.
ES2067154T3 (es) Dibenzoilalquilcianohidracinas.
ES2164088T3 (es) Antagonistas de la sustancia p para el tratamiento de la emesis.
ATE181329T1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
BR9916114A (pt) Uso de apomorfina na fabricação de um medicamento para tratamento de disfunção erétil orgânica masculina
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
ATE278382T1 (de) Verwendung von ellagsäure zum schutz gegen verschmutzung
BR0306306A (pt) Composição contendo extrato de matricária e uso desta
ES2165029T3 (es) Hidrofluoruros de amina y su utilizacion como agentes para la higiene bucal.